|
|
|
|
|
Product Name
|
Calpain 9 peptide (Carboxyterminal end domain V)
|
|
Product type
|
Proteins and Peptides
|
|
Peptide
|
This peptide was used as an immunogen for ab28218 - Calpain 9 antibody - Domain IV (EF-1) and large subunit.
|
|
Specificity
|
We have a range of domain specific antibodies for this target. For a full list please see all Calpain 9 antibodies
|
|
Tested applications
(see key)
|
ELISA, WB
|
|
Application notes
(see key)
|
Recommended dilutions
ELISA: Use at an assay dependent dilution. WB: Use at an assay dependent dilution. This peptide can be used with studies using ab28218. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
|
|
Research areas
|
Cell Biology >> Proteolysis / Ubiquitin >> Proteolytic enzymes >> Cysteine protease >> Calpains
Signal Transduction >> Signaling Pathway >> Calcium Signaling >> Calpain
|
|
Relevance
|
Calpain 9 is an intracellular, calcium dependent cysteine protease. Calpain 9 was first described in the digestive tract, and a shorter form with a deletion in the catalytic domain has been associated with gastric cancer. Recombinant calpain 9 has been expressed, and is unstable unless expressed with the calpain small subunit (calpain S1), suggesting that calpain 9 associates with the small subunit in vivo. The recombinant calpain 9 showed caseinolytic activity, albeit at a lower level than native calpain 1 or calpain 2, and a calcium sensitivity intermediate between calpain 1 and calpain 2. Calpastatin blocked the caseinolytic activity. Domains in the large subunit include the amino terminal domain I, the proteinase domain II, domain III, and the EF hand domain IV. The latent large subunit migrates at about 79 kD on reduced SDS PAGE gels, and truncation at the amino terminal end yields an approximately 58 kD form. A cascade of smaller forms can be seen with further activation. It is expressed predominantly in the stomach although a shorter form with a deletion in the catalytic domain has been associated with gastric cancer.
|
|
|
Calpain 9 peptide (Carboxyterminal end domain V) (ab41358) |
|
Purity
|
>95% by SDS-PAGE
|
|
Storage buffer
|
Preservative: None
Constituents: 0.001% Tween 20, 30mM HEPES, 2mM EDTA, 150mM Sodium chloride, pH 6.75
|
|
Form
|
Liquid
|
|
Concentration
|
1.000 mg/ml
|
|
Storage instructions
|
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
|
| |
At Abcam, we have one centralized database to hold all of our product information, so that everything we know about this Calpain 9 peptide (Carboxyterminal end domain V) is on this datasheet. But please do contact us if you would like any reassurance! |
 |
|
| |
|
Search PubMed (MEDLINE) for references to Calpain 9
|
| |
Calpain 9 peptide (Carboxyterminal end domain V) - more information
|
Customer reviews (feedback) regarding Calpain 9 peptide (Carboxyterminal end domain V) |
Customer FAQs regarding Calpain 9 peptide (Carboxyterminal end domain V) |
Protocols for Calpain 9 peptide (Carboxyterminal end domain V) |
Price and availability of products related to Calpain 9 peptide (Carboxyterminal end domain V) |
| |
Calpain 9 peptide (Carboxyterminal end domain V) - related products:
|
|
|
| |
Calpain 9 peptide (Carboxyterminal end domain V) - other tools:
|
Contact Abcam with a Technical Enquiry about Calpain 9 peptide (Carboxyterminal end domain V) |
| |
All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
Pricing information loading
